Search - tctmd.com

Displaying 921 - 940 of 1925

Sort: Relevancy | Date

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News Features

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Shelley Wood

April 21, 2020

News Daily News

Smartphones Aid in Remote Monitoring of Patients With Recent Acute MI

L.A. McKeown

April 21, 2020

Presentation

Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI

April 15, 2020

News Daily News

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Michael O'Riordan

April 15, 2020

News Opinion CV Team Dispatch

April 2020 News Roundup

L.A. McKeown

April 10, 2020

News Daily News

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

Michael O'Riordan

April 08, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News ACC 2020

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

Caitlin E. Cox

March 31, 2020

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation ACC 2020

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

Presenter: Mark Eisenberg

March 30, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Conference News ACC 2020

Increased Physical Activity on Apple Watch Lowers BP

Yael L. Maxwell

March 23, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

AHA: Advice on Lifestyle, Risk Factor Modification to Cut A-fib Events

Yael L. Maxwell

March 13, 2020

Advertisement

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Smartphones Aid in Remote Monitoring of Patients With Recent Acute MI

Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

April 2020 News Roundup

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

A Randomized Controlled Trial Evaluating the Efficacy and Safety of E-Cigarettes for Smoking Cessation

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Increased Physical Activity on Apple Watch Lowers BP

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

AHA: Advice on Lifestyle, Risk Factor Modification to Cut A-fib Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content